US Stock Insider Trading | Supernus Discloses 4 Insider Transactions on February 26

K-LinePoet · 2026-02-26T22:05:45+00:00

On February 26, 2026, Supernus Pharmaceuticals disclosed insider trading activities of several executives, mainly selling shares, with trading dates concentrated on February 24 to 25. The company focuses on the treatment of central nervous system diseases and the development of new products.

K-LinePoet

2026-02-26 22:05:45

Abstract generation in progress

On February 26, 2026, Supernus (SUPN) disclosed four insider trading transactions. Executive DEC TIMOTHY C sold 1,279 shares on February 25, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 26, 2026	Executive	Bhatt Padmanabh P.	February 25, 2026	Sell	650	50.69	32,900
February 26, 2026	Executive	DEC TIMOTHY C	February 25, 2026	Sell	1,279	50.69	64,800
February 26, 2026	Executive	Rubin Jonathan	February 25, 2026	Sell	675	50.69	34,200
February 26, 2026	Executive	Mottola Frank	February 25, 2026	Sell	977	50.69	49,500
February 25, 2026	Executive	Bhatt Padmanabh P.	February 24, 2026	Sell	581	51.35	29,800
February 25, 2026	Executive	Rubin Jonathan	February 24, 2026	Sell	603	51.35	31,000
February 25, 2026	Executive	Mottola Frank	February 24, 2026	Sell	1,038	50.86	52,800
February 25, 2026	Executive	DEC TIMOTHY C	February 24, 2026	Sell	603	51.35	31,000
February 25, 2026	Director	GEMAYEL GEORGES	February 23, 2026	Buy	15,000	12.98	194,700
February 25, 2026	Executive	DEC TIMOTHY C	February 24, 2026	Sell	1,766	50.86	89,800

[Company Profile]

Supernus Pharmaceuticals, Inc. was incorporated in Delaware on March 30, 2005, and began operations on December 22, 2005. The company is a biopharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its diversified neuroscience product portfolio includes approved treatments for attention deficit hyperactivity disorder (ADHD), motor impairments in Parkinson’s disease patients receiving levodopa therapy, low activity in Parkinson’s disease, epilepsy, migraines, cervical dystonia, and chronic sialorrhea. The company is also developing a broad range of new CNS candidates, including potential therapies for epilepsy, depression, and other CNS diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes